chartexchange

Lyell Immunopharma To Participate in November Investor Events

GlobeNewswire Inc. | Nov 2, 2026 8:00 AM EST

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in the following investor events:

Read original article